العربية
中国
Français
Deutsch
Ελληνική
हिन्दी
Italiano
日本語
Português
Русский
EspañolPAMIDRONIC ACID
(Redirected from Pamidronate)
'Pamidronic acid' (INN) or 'pamidronate disodium' (USAN), marketed as 'pamidronate disodium pentahydrate' under the brand name 'Aredia®', is a bisphosphonate.
It is used to prevent bone loss, and treat osteoporosis. It is also used to strengthen bone in Paget's disease, to prevent bone loss due to steroid use, and in certain cancers with high propensity to bone, such as multiple myeloma. In multiple myeloma, it is usually administered as an intravenous infusion, lasting about 3 hours. The therapy is repeated monthly, and lasts for the life of the patient. Due to its ability to sequester calcium in bone, it is also used to treat high calcium levels.
Intravenous, usually 90 mg monthly. 30 mg, 60 mg, and 90 mg vials are available, mixed with mannitol.
Common side effects include bone pain, low calcium levels, nausea, and dizziness.
Osteonecrosis of the jaw is a rare complication which has been associated with the use of bisphosphonates, including pamidronate. Osteonecrosis of the jaw associated with pamidronate therapy., Zarychanski R, Elphee E, Walton P, Johnston J, , , Am J Hematol, 2006
Pamidronate activates human γδ T cells ''in vitro'' and ''in vivo'', which may lead to flu-like symptoms upon administration.
'Pamidronic acid' (INN) or 'pamidronate disodium' (USAN), marketed as 'pamidronate disodium pentahydrate' under the brand name 'Aredia®', is a bisphosphonate.
| Contents |
| Uses |
| Administration |
| Side effects |
| References |
Uses
It is used to prevent bone loss, and treat osteoporosis. It is also used to strengthen bone in Paget's disease, to prevent bone loss due to steroid use, and in certain cancers with high propensity to bone, such as multiple myeloma. In multiple myeloma, it is usually administered as an intravenous infusion, lasting about 3 hours. The therapy is repeated monthly, and lasts for the life of the patient. Due to its ability to sequester calcium in bone, it is also used to treat high calcium levels.
Administration
Intravenous, usually 90 mg monthly. 30 mg, 60 mg, and 90 mg vials are available, mixed with mannitol.
Side effects
Common side effects include bone pain, low calcium levels, nausea, and dizziness.
Osteonecrosis of the jaw is a rare complication which has been associated with the use of bisphosphonates, including pamidronate. Osteonecrosis of the jaw associated with pamidronate therapy., Zarychanski R, Elphee E, Walton P, Johnston J, , , Am J Hematol, 2006
Pamidronate activates human γδ T cells ''in vitro'' and ''in vivo'', which may lead to flu-like symptoms upon administration.
References
This article provided by Wikipedia. To edit the contents of this article, click here for original source.
psst.. try this: add to faves
